{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:41:59Z","timestamp":1760186519064,"version":"build-2065373602"},"reference-count":126,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.hoc.2016.07.014","type":"journal-article","created":{"date-parts":[[2016,11,24]],"date-time":"2016-11-24T01:04:27Z","timestamp":1479949467000},"page":"1345-1370","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Mantle Cell Lymphoma"],"prefix":"10.1016","volume":"30","author":[{"given":"Andre","family":"Goy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2016.07.014_bib1","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/1097-0142(19820401)49:7<1429::AID-CNCR2820490720>3.0.CO;2-5","article-title":"Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma","volume":"49","author":"Weisenburger","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib2","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A\u00a0revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.6093263","article-title":"Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation","volume":"226","author":"Tsujimoto","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.hoc.2016.07.014_bib4","first-page":"1437","article-title":"Chromosome t(11;14)(q13;q32) breakpoints in centrocytic lymphoma are highly localized at the bcl-1 major translocation cluster","volume":"7","author":"Williams","year":"1993","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.07.014_bib5","doi-asserted-by":"crossref","first-page":"5524","DOI":"10.1182\/blood-2007-08-109611","article-title":"Borrelia infection and risk of non-Hodgkin lymphoma","volume":"111","author":"Schollkopf","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib6","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/jncimonographs\/lgu007","article-title":"Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","volume":"2014","author":"Smedby","year":"2014","journal-title":"J\u00a0Natl Cancer Inst Monogr"},{"key":"10.1016\/j.hoc.2016.07.014_bib7","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1182\/blood.V126.23.2685.2685","article-title":"LRPAP1 is a frequent B-cell receptor antigen in mantle cell lymphoma (MCL)","volume":"126","author":"Thurner","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib8","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.hoc.2016.07.014_bib9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/gcc.20754","article-title":"Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma","volume":"49","author":"Espinet","year":"2010","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib10","first-page":"49","article-title":"Management of mantle cell lymphoma","volume":"12","author":"Armitage","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.hoc.2016.07.014_bib11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/(SICI)1098-2264(199810)23:2<175::AID-GCC11>3.0.CO;2-N","article-title":"Detection of t(11;14) using interphase molecular cytogenetics in mantle cell lymphoma and atypical chronic lymphocytic leukemia","volume":"23","author":"Avet-Loiseau","year":"1998","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib12","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1182\/blood-2007-10-120824","article-title":"Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression","volume":"111","author":"Herens","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib13","doi-asserted-by":"crossref","first-page":"5683","DOI":"10.1182\/blood-2007-10-118794","article-title":"Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas","volume":"111","author":"Wlodarska","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.hoc.2016.07.014_bib15","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib16","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/cncr.11096","article-title":"Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma","volume":"97","author":"Romaguera","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib17","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic involvement is a common feature in mantle cell lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib18","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/annonc\/mdm447","article-title":"Central nervous system involvement in mantle cell lymphoma","volume":"19","author":"Ferrer","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib19","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdt139","article-title":"Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network","volume":"24","author":"Cheah","year":"2013","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2016.07.014_bib20","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdv074","article-title":"Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL)","volume":"26","author":"Chihara","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib21","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2008.16.8435","article-title":"Improvement of overall survival in advanced stage mantle cell lymphoma","volume":"27","author":"Herrmann","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib22","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1182\/blood-2014-03-559930","article-title":"Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study","volume":"124","author":"Abrahamsson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.07.014_bib23","first-page":"44","article-title":"Mantle cell lymphoma: state of the art","volume":"13","author":"Skarbnik","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib24","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib25","doi-asserted-by":"crossref","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","article-title":"Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909","volume":"27","author":"Damon","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","article-title":"Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC\u00a0+ autologous stem-cell support: still very long survival but late relapses do occur","volume":"158","author":"Geisler","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib27","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in\u00a0vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib28","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.151.151","volume":"120","author":"Hermine","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib29","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.147.147","article-title":"MRD eradication should be the therapeutic goal in mantle cell lymphoma and may enable tailored treatment approaches: results of the intergroup trials of the European MCL Network","volume":"124","author":"Pott","year":"2014","journal-title":"Blood"},{"issue":"10044","key":"10.1016\/j.hoc.2016.07.014_bib31","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.07.014_bib32","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.13796","article-title":"Rituximab plus hyper-CVAD alternating with MTX\/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center","volume":"172","author":"Chihara","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib34","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A\u00a0phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib36","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib37","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1080\/10428190801923725","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"49","author":"Till","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.07.014_bib38","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood.V126.23.338.338","volume":"126","author":"Callanan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood.V126.23.518.518","volume":"126","author":"Chen","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2016.07.014_bib40","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/bjh.13929","article-title":"A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma","volume":"173","author":"Armand","year":"2016","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.hoc.2016.07.014_bib41","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.3109\/10428194.2013.825906","article-title":"High dose cytarabine with rituximab is not enough in first-line treatment of mantle cell lymphoma with high proliferation: early closure of the Nordic Lymphoma Group MantleCell Lymphoma 5 trial","volume":"55","author":"Laurell","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.07.014_bib42","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.bbmt.2014.08.019","article-title":"Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma","volume":"20","author":"Dahi","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.hoc.2016.07.014_bib43","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.3109\/10428194.2012.656628","article-title":"Survival trends in mantle cell lymphoma in the United States over sixteen years 1992-2007","volume":"53","author":"Chandran","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"14","key":"10.1016\/j.hoc.2016.07.014_bib44","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1002\/cncr.26731","article-title":"Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD","volume":"118","author":"Mato","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib45","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.337.337","article-title":"Bortezomib maintenance (BM) versus consolidation (BC) following aggressive immunochemotherapy and autologous stem cell transplant (ASCT) for untreated mantle cell lymphoma (MCL): CALGB (ALLIANCE) 50403","volume":"126","author":"Kaplan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib46","volume":"124","author":"Le Gouill","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib47","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib48","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2016.07.014_bib49","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib50","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1080\/10428190802688509","article-title":"Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study","volume":"50","author":"Eve","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.hoc.2016.07.014_bib51","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.hoc.2016.07.014_bib52","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.07.014_bib53","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of Older Patients with Mantle-Cell Lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2016.07.014_bib54","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1412096","article-title":"Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma","volume":"372","author":"Robak","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.hoc.2016.07.014_bib55","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/annonc\/mdl127","article-title":"Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network","volume":"17","author":"Kahl","year":"2006","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib56","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1365-2141.2011.08820.x","article-title":"VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: a Wisconsin Oncology Network study","volume":"155","author":"Chang","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib57","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2013-08-523845","article-title":"Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405)","volume":"123","author":"Chang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib58","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2010-11-314708","article-title":"The combination of bendamustine, bortezomib, and rituximab for patients with relapsed\/refractory indolent and mantle cell non-Hodgkin lymphoma","volume":"117","author":"Friedberg","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib59","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V122.21.370.370","article-title":"The RIBVD regimen (rituximab IV, bendamustine IV, velcade SC, dexamethasone IV) offers a high complete response rate in elderly patients with untreated mantle cell lymphoma. Preliminary results of the lysa trial \u201cLymphome Du Manteau 2010 SA\u201d","volume":"122","author":"Gressin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-03-704023","article-title":"Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4","author":"Albertsson-Lindblad","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.hoc.2016.07.014_bib61","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","article-title":"Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma","volume":"29","author":"Hess","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.hoc.2016.07.014_bib62","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","volume":"31","author":"Visco","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/leu.2014.223","article-title":"The EBMT\/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma","volume":"29","author":"Robinson","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.07.014_bib64","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.29498","article-title":"Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning","volume":"121","author":"Vaughn","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.hoc.2016.07.014_bib65","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2005.03.108","article-title":"Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"23","author":"Goy","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib66","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib67","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"29","key":"10.1016\/j.hoc.2016.07.014_bib68","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib69","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.014_bib70","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Postibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2016.07.014_bib71","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2012.45.9438","article-title":"Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma","volume":"31","author":"Hunstig","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2016.07.014_bib72","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/bjh.12769","article-title":"Ofatumumab monotherapy in relapsed\/refractory mantle cell lymphoma\u2013a phase II trial","volume":"165","author":"Furtado","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S1470-2045(15)00438-6","article-title":"Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial","volume":"17","author":"Wang","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib74","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1182\/blood-2014-01-547869","article-title":"Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity","volume":"123","author":"Kohrt","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib75","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib76","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.hoc.2016.07.014_bib77","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1182\/blood-2015-10-673145","article-title":"Post-ibrutinib outcomes in patients with mantle cell lymphoma","volume":"127","author":"Martin","year":"2016","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.hoc.2016.07.014_bib78","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A phase 1 study of the PI3K\u03b4 inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.hoc.2016.07.014_bib79","article-title":"Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies","volume":"33","author":"O'Brien","year":"2015","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2016.07.014_bib80","article-title":"Safety and activity of the chemotherapy-free triplet of ublituximab, TGR-1202, and ibrutinib in relapsed B-cell malignancies","volume":"33","author":"Fowler","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib81","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A Phase 1 Study of Venetoclax (ABT-199 \/ GDC-0199) Monotherapy in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib82","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib83","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1200\/JCO.2013.52.2466","article-title":"Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network","volume":"32","author":"Hoster","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer cell"},{"key":"10.1016\/j.hoc.2016.07.014_bib85","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib86","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1182\/blood-2009-08-236570","article-title":"The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)","volume":"115","author":"Geisler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib87","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1182\/blood-2010-01-263806","article-title":"Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling","volume":"116","author":"Hartmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib88","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","article-title":"Landscape of somatic mutations and clonal evolution in mantle cell lymphoma","volume":"110","author":"Bea","year":"2013","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.hoc.2016.07.014_bib89","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1182\/blood-2011-07-370122","article-title":"Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis","volume":"119","author":"Iqbal","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib90","doi-asserted-by":"crossref","first-page":"e19736","DOI":"10.1371\/journal.pone.0019736","article-title":"Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma","volume":"6","author":"Enjuanes","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.hoc.2016.07.014_bib91","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"Suppl","key":"10.1016\/j.hoc.2016.07.014_bib92","article-title":"Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies","volume":"34","author":"Scott","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib93","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1158\/1078-0432.CCR-14-0836","article-title":"New paradigms in mantle cell lymphoma: is it time to risk-stratify treatment based on the proliferative signature?","volume":"20","author":"Dreyling","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.07.014_bib94","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.1740.1740","article-title":"Subcutaneous (SQ) bortezomib (BTZ) in patients (patients) with relapsed mantle cell lymphoma (MCL): retrospective, observational study of treatment patterns and outcomes in US community oncology practices","volume":"124","author":"Skarbnik","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib95","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2141.2010.08315.x","article-title":"Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma","volume":"151","author":"Romaguera","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib96","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A\u00a0phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O'Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2016.07.014_bib97","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib98","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1038\/leu.2015.60","article-title":"Safety and efficacy of Temsirolimus in combination with Bendamustine and Rituximab in relapsed mantle cell and follicular lymphoma","volume":"29","author":"Hess","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.hoc.2016.07.014_bib99","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1093\/annonc\/mdu273","article-title":"Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma","volume":"25","author":"Inwards","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib100","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/bjh.12780","article-title":"Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study","volume":"165","author":"Wang","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.hoc.2016.07.014_bib101","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","article-title":"A\u00a0phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL)","volume":"123","author":"Kahl","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib102","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib103","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3935.3935","article-title":"Results of the mantle cell lymphoma subset from a phase 2a study of copanlisib, a novel PI3K inhibitor, in patients with indolent and aggressive lymphoma","volume":"126","author":"Cunningham","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib104","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.254.254","article-title":"A\u00a0phase 1 study of venetoclax (ABT-199\/GDC-0199) monotherapy in patients with relapsed\/refractory non-hodgkin lymphoma","volume":"126","author":"Gerecitano","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib105","article-title":"A\u00a0dose-escalation study of venetoclax (ABT-199\/GDC-0199) in combination with bendamustine and rituximab in patients with relapsed or refractory non-Hodgkin's lymphoma","volume":"126","author":"Sven de Vos","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib106","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1182\/blood-2011-10-388298","article-title":"Selective CDK4\/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma","volume":"119","author":"Leonard","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib107","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2016.07.014_bib108","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.2010.32.1398","article-title":"Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma","volume":"29","author":"Kirschbaum","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib109","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1200\/JCO.2012.46.9585","article-title":"Obinutuzumab (GA101) monotherapy in relapsed\/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study","volume":"31","author":"Morschhauser","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib110","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1200\/JCO.2012.45.9438","article-title":"Complete remission after treatment with single-agent ofatumumab in a patient with high-risk leukemic mantle-cell lymphoma","volume":"31","author":"Hunstig","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.hoc.2016.07.014_bib111","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3980.3980","article-title":"Ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody, in combination with ibrutinib is highly active in patients with relapsed and\/or refractory mantle cell lymphoma; results of a phase II Trial","volume":"126","author":"Kolibaba","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib112","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2016.07.014_bib113","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1182\/blood-2011-09-370320","article-title":"CHOP and DHAP plus rituximab followed by autologous stem cell transplantation inmantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte","volume":"121","author":"Delarue","year":"2013","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.hoc.2016.07.014_bib114","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/blood-2008-03-147025","article-title":"Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group","volume":"112","author":"Geisler","year":"2008","journal-title":"Blood"},{"issue":"10044","key":"10.1016\/j.hoc.2016.07.014_bib115","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.hoc.2016.07.014_bib116","volume":"124","author":"Le Gouill","year":"2014","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.hoc.2016.07.014_bib117","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1182\/blood-2013-12-541953","article-title":"Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM\/C in non-CR patients before transplant in mantle cell lymphoma","volume":"123","author":"Kolstad","year":"2014","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.hoc.2016.07.014_bib118","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2016.07.014_bib119","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/annonc\/mdt070","article-title":"A phase II multicenter trial of hyperCVAD MTX\/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213","volume":"24","author":"Bernstein","year":"2013","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2016.07.014_bib120","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1365-2141.2011.08958.x","article-title":"Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi","volume":"156","author":"Merli","year":"2012","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.hoc.2016.07.014_bib121","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"issue":"9873","key":"10.1016\/j.hoc.2016.07.014_bib122","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.hoc.2016.07.014_bib123","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.hoc.2016.07.014_bib124","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1200\/JCO.2012.45.9842","article-title":"Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation","author":"Visco","year":"2013","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2016.07.014_bib125","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2012.42.2444","article-title":"Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499","volume":"30","author":"Smith","year":"2012","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.hoc.2016.07.014_bib126","volume":"34","author":"Rummel","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858816301022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:04:05Z","timestamp":1760184245000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858816301022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":126,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["S0889858816301022"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2016.07.014","relation":{},"ISSN":["0889-8588"],"issn-type":[{"type":"print","value":"0889-8588"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mantle Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2016.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}